Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Beam Therapeutics Inc. before investing. In this article, we go over a few key ...

Shares of gene therapy companies — including Sarepta Therapeutics, Avidity Biosciences and Beam Therapeutics — got a lift Monday after Food and Drug Administration Commissioner Marty Makary laid out ...

Beam Therapeutics Inc. (NASDAQ:BEAM) on Saturday presented additional data from the Phase 1/2 clinical trial of BEAM-302 in ...

Shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) have earned an average recommendation of “Buy” from the fourteen brokerages that are presently covering the company, Marketbeat reports ...

Beam Therapeutics (BEAM) saw its shares surge in the last session with trading volume being higher than average. The latest ...

Mitsubishi UFJ Asset Management Co. Ltd. lowered its position in Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 9.4% during the fourth quarter, according to its most recent Form 13F filing with ...

In this article, we are going to take a look at where Beam Therapeutics Inc. (NASDAQ:BEAM) stands against other best gene-editing stocks to buy. Gene editing is an advanced medical technique ...

Beam Therapeutics (BEAM) presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Scotiabank analyst Greg Harrison maintained a Buy rating on Beam Therapeutics (BEAM – Research Report) today and set a price target of $40.00.

Beam Therapeutics (BEAM) said that the U.S. FDA cleared the investigational new drug application for BEAM-302 for the treatment of alpha-1 antitrypsin deficiency (AATD), a genetic condition ...

Beam Therapeutics specializes in developing base-edited therapies for rare diseases and cancers. The company’s proprietary base editing platform allows for precise genetic modifications without ...